However, given the preclinical successes of the newer antihyperglycemicagents of the sodium glucose cotransporter-2 (SGLT2) inhibitor [293] andglucagon-like peptide-1 (GLP1) receptor agonist [294] on the treatment ofexperimental PH and in human trials of heart failure with PH in general, it isexpected that these drugs will soon advance to clinical trials in PAH. Here, SLC5A2 is linked to pulmonary arterial hypertension.